Profil bibliographique

Melinda Soeung

Informations fournies par OpenAlex. Research Africa ne déduit ni nationalité, ni poste, ni coordonnées personnelles.

121Publications signalées

744Citations signalées

2Affiliations récentes

Les institutions déclarées

The University of Texas MD Anderson Cancer Center Dana-Farber Cancer Institute

Les domaines associés

Chromatin Remodeling and CancerRenal cell carcinoma treatmentMechanisms of cancer metastasisFerroptosis and cancer prognosisPancreatic and Hepatic Oncology Research

Les publications récentes

Accès ouvert 2026 supplementary-materials OpenAlex

Supplementary Figure S5 from Phase II Trial of Ixazomib Combined with Gemcitabine and Doxorubicin in Patients with SMARCB1-Deficient Renal Medullary Carcinoma

Kai Yu, Rebecca S. Slack Tidwell, Tharakeswara Kumar Bathala, Rahul A. Sheth et autres

Single-cell landscape of TME and epithelial cells from longitudinally collected tumor samples at baseline and during trial therapy.

0 citations

Accès ouvert 2026 supplementary-materials OpenAlex

Supplementary Table S5 from Phase II Trial of Ixazomib Combined with Gemcitabine and Doxorubicin in Patients with SMARCB1-Deficient Renal Medullary Carcinoma

Kai Yu, Rebecca S. Slack Tidwell, Tharakeswara Kumar Bathala, Rahul A. Sheth et autres

Stopping criteria for futility.

0 citations

Accès ouvert 2026 supplementary-materials OpenAlex

Supplementary Appendix S1 from Phase II Trial of Ixazomib Combined with Gemcitabine and Doxorubicin in Patients with SMARCB1-Deficient Renal Medullary Carcinoma

Kai Yu, Rebecca S. Slack Tidwell, Tharakeswara Kumar Bathala, Rahul A. Sheth et autres

List of Patient Mosaic Team and Rare Tumors Initiative collaborators

0 citations

Accès ouvert 2026 supplementary-materials OpenAlex

Supplementary Figure S3 from Phase II Trial of Ixazomib Combined with Gemcitabine and Doxorubicin in Patients with SMARCB1-Deficient Renal Medullary Carcinoma

Kai Yu, Rebecca S. Slack Tidwell, Tharakeswara Kumar Bathala, Rahul A. Sheth et autres

Duration of response in patients treated with ixazomib plus gemcitabine plus doxorubicin.

0 citations

Accès ouvert 2026 supplementary-materials OpenAlex

Supplementary Figure S4 from Phase II Trial of Ixazomib Combined with Gemcitabine and Doxorubicin in Patients with SMARCB1-Deficient Renal Medullary Carcinoma

Kai Yu, Rebecca S. Slack Tidwell, Tharakeswara Kumar Bathala, Rahul A. Sheth et autres

Overall survival from treatment initiation with ixazomib plus gemcitabine plus doxorubicin.

0 citations

Accès ouvert 2026 supplementary-materials OpenAlex

Supplementary Table S10 from Phase II Trial of Ixazomib Combined with Gemcitabine and Doxorubicin in Patients with SMARCB1-Deficient Renal Medullary Carcinoma

Kai Yu, Rebecca S. Slack Tidwell, Tharakeswara Kumar Bathala, Rahul A. Sheth et autres

Treatment emergent adverse events regardless of attribution.

0 citations

Accès ouvert 2026 supplementary-materials OpenAlex

Supplementary Table S2 from Phase II Trial of Ixazomib Combined with Gemcitabine and Doxorubicin in Patients with SMARCB1-Deficient Renal Medullary Carcinoma

Kai Yu, Rebecca S. Slack Tidwell, Tharakeswara Kumar Bathala, Rahul A. Sheth et autres

Dose adjustments of trial therapy.

0 citations

Accès ouvert 2026 supplementary-materials OpenAlex

Supplementary Table S9 from Phase II Trial of Ixazomib Combined with Gemcitabine and Doxorubicin in Patients with SMARCB1-Deficient Renal Medullary Carcinoma

Kai Yu, Rebecca S. Slack Tidwell, Tharakeswara Kumar Bathala, Rahul A. Sheth et autres

Treatment emergent adverse events at least possibly related to study therapy.

0 citations

Accès ouvert 2026 supplementary-materials OpenAlex

Supplementary Table S11 from Phase II Trial of Ixazomib Combined with Gemcitabine and Doxorubicin in Patients with SMARCB1-Deficient Renal Medullary Carcinoma

Kai Yu, Rebecca S. Slack Tidwell, Tharakeswara Kumar Bathala, Rahul A. Sheth et autres

Number of tumor cells in scRNA-seq analysis from the 11 patients with RMC.

0 citations

Accès ouvert 2026 supplementary-materials OpenAlex

Supplementary Table S4 from Phase II Trial of Ixazomib Combined with Gemcitabine and Doxorubicin in Patients with SMARCB1-Deficient Renal Medullary Carcinoma

Kai Yu, Rebecca S. Slack Tidwell, Tharakeswara Kumar Bathala, Rahul A. Sheth et autres

Operating characteristics under varying trial-limiting toxicities rates.

0 citations

Accès ouvert 2026 supplementary-materials OpenAlex

Supplementary Table S7 from Phase II Trial of Ixazomib Combined with Gemcitabine and Doxorubicin in Patients with SMARCB1-Deficient Renal Medullary Carcinoma

Kai Yu, Rebecca S. Slack Tidwell, Tharakeswara Kumar Bathala, Rahul A. Sheth et autres

Patient samples used for single-cell RNA sequencing and whole exome sequencing.

0 citations

Accès ouvert 2026 supplementary-materials OpenAlex

Supplementary Figure S6 from Phase II Trial of Ixazomib Combined with Gemcitabine and Doxorubicin in Patients with SMARCB1-Deficient Renal Medullary Carcinoma

Kai Yu, Rebecca S. Slack Tidwell, Tharakeswara Kumar Bathala, Rahul A. Sheth et autres

Molecular characterization of malignant epithelial subtypes.

0 citations

Profil ORCID Notice OpenAlex

BNTIC News n’est pas le producteur de ces données. Les publications sont interrogées à la demande dans Crossref, OpenAIRE, DOAJ, Europe PMC, HAL, DataCite, AfricArXiv, ROR et la Banque mondiale, sans clé d’accès. OpenAlex reste optionnel. Aucun service payant n’est nécessaire et aucune donnée externe n’est enregistrée en base. Consulter les sources et leurs limites.